MedTrace Logo

Study of the Durability of Glycemic Control With Nateglinide

NCT00858013 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-05-16

Study results available
· View outcomes & findings →

Summary

This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.

Conditions

Interventions

DRUG

Nateglinide

Nateglinide 90\~120mg three times a day

DRUG

Glimepiride

Glimepiride 1\~2mg once a day

Sponsors & Collaborators

  • Korea University Guro Hospital

    collaborator OTHER

  • Hanyang University

    collaborator OTHER

  • Inha University Hospital

    collaborator OTHER

  • Kyunghee University Medical Center

    collaborator OTHER

  • Myongji Hospital

    collaborator OTHER

  • Bundang CHA Hospital

    collaborator OTHER

  • Wonju Severance Christian Hospital

    collaborator OTHER

  • Hallym University Medical Center

    collaborator OTHER

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Kwan Woo Lee, MD,PhD · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-24
Primary Completion
2014-06-25
Completion
2014-06-25

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858013 on ClinicalTrials.gov